

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-------------------------------|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/716,975 |
| | | | | Filing Date | November 19, 2003 |
| | | | | First Named Inventor | Ekwurilie, Nnochiri N., et al. |
| | | | | Art Unit | 1651 |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | 014811-29.8DV3 |
| Sheet | 1 | of | 1 | | |

NON PATENT LITERATURE DOCUMENTS

| | | | |
|-----------------------|-----------|--------------------|---------|
| Examiner Signature | R.G.TOMEN | Date Considered | 11/4/04 |
|-----------------------|-----------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Applicant's Unique Citation Designation Number (optional). Applicant is to place a check mark here if designating a unique citation number. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

| FORM PTO-1449 | | US Dept. of Commerce Patent and Trademark Office | | ATTORNEY DOCKET NO. 9233.8DV3 4012-113 | SERIAL NO. To be assigned 09/134,803 | | |
|---|----|--|--------------|---|---|----------|----------------------------|
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANT Nnochiri N. Ekwuribe | | | | | |
| | | FILING DATE Concurrently herewith August 14, 1998 | | GROUP 1651 1646 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| <i>RG</i> | AA | 4,585,754 | 29 Apr. 1986 | Meisner et al. | | | |
| | AB | 4,179,337 | 18 Dec. 1979 | Davis et al. | | | |
| | AC | 4,003,792 | 18 Jan. 1977 | Mills et al. | | | |
| | AD | 4,849,405 | 18 Jul. 1989 | Ecanow | | | |
| | AE | 5,013,556 | 7 May 1991 | Woodle et al. | | | |
| | AF | 4,963,367 | 16 Oct. 1990 | Ecanow | | | |
| | AG | 4,044,196 | 23 Aug. 1977 | Hüper et al. | | | |
| | AH | 4,717,566 | 5 Jan. 1988 | Eckenhoff et al. | | | |
| | AI | 4,698,264 | 6 Oct. 1987 | Steinke | | | |
| | AJ | 4,684,524 | 4 Aug. 1987 | Eckenhoff et al. | | | |
| | AK | 4,410,547 | 18 Oct. 1983 | Ueno et al. | | | |
| | AL | 3,256,153 | 14 Jun. 1966 | Heimlich | | | |
| | AM | 4,935,246 | 19 Jun. 1990 | Ahrens | | | |
| | AN | 4,797,288 | 10 Jan 1989 | Sharma et al. | | | |
| | AO | 4,744,976 | 17 May 1988 | Snipes et al. | | | |
| | AP | 5,055,304 | 8 Oct. 1991 | Makino et al. | | | |
| | AQ | 5,055,300 | 8 Oct. 1991 | Gupta | | | |
| | AR | 4,772,471 | 20 Sep. 1988 | Vanlerberghe et al. | | | |
| | AS | 5,093,198 | 3 Mar. 1992 | Speaker et al. | | | |
| | AT | 4,840,799 | 20 Jun. 1989 | Appelgren et al. | | | |
| | AU | 4,622,392 | 11 Nov. 1986 | Hong et al. | | | |
| | AV | 5,653,987 | 5 Aug. 1997 | Modi et al. | | | |
| | AW | 5,792,834 | 11 Aug. 1998 | Hakimi et al. | | | |
| | AX | 5,595,732 | 21 Jan. 1997 | Hakimi et al. | | | |
| | AY | 5,539,063 | 23 Jul. 1996 | Hakimi et al. | | | |
| Continue on page 2 | | | | | | | |
| EXAMINER <i>RG Dommen</i> | | | | | DATE CONSIDERED <i>11/4/04</i> | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | | | | |

| FORM PTO-1449 | | US Dept. of Commerce Patent and Trademark Office | | ATTORNEY DOCKET NO. <i>4012-113 9233.8DV3</i> | | SERIAL NO. <i>To be assigned</i> <i>09/134,803</i> | |
|---|----|---|------------------|--|-------|--|----------------------------|
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANT <i>Nnochiri N. Ekwuribe</i> | | | | | |
| | | FILING DATE <i>Concurrently herewith</i> <i>August 14, 1998</i> | | GROUP <i>1646</i> | | <i>1651</i> | |
| EXAMINER INITIAL | | PATENT NUMBER | ISSUE DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| <i>RG</i> | AZ | 5,559,213 | 24 Sep 1996 | Hakimi et al. | | | |
| | BA | 5,747,646 | 5 May 1998 | Hakimi et al. | | | |
| | BB | 5,286,637 | 15 Feb. 1994 | Veronese et al. | | | |
| | BC | 5,631,263 | 20 May 1997 | Portoghesi et al. | | | |
| | BD | 5,602,099 | 11 Feb. 1997 | Schiller | | | |
| | BE | 5,545,719 | 13 Aug. 1996 | Shashoua et al. | | | |
| | BF | 5,641,861 | 24 Jun. 1997 | Dooley et al. | | | |
| | BG | 5,663,295 | 2 Sep. 1997 | Moreau et al. | | | |
| | BH | 5,786,447 | 28 Jul. 1998 | Schiller et al. | | | |
| | BI | 4,939,174 | 3 Jul. 1990 | Shashoua | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | PUBLICATION DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | BJ | WO93/01802 | 4 Feb. 1993 | PCT/Switzerland | | | X |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | | | | |
| | BK | Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8 (12): pp. 1453-1459. | | | | | |
| | BL | Bocci, E. et al., "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982, 14: pp. 11-120. | | | | | |
| | BM | Igarashi, R. et al., "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater. 1990, 17: pp. 367-368. | | | | | |
| | BN | Taniguchi, T. et al., "Synthesis of Acyloyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats," Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater., 1992, 19: pp. 104-105. | | | | | |
| | BO | Russell-Jones, G. J., "Vitamin B12 Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioactive. Mater., 1992; 19: pp. 102-103. | | | | | |
| | BP | Baudys, M. et al., "Synthesis and Characteristics of Different Glycosylated Derivatives of Insulin," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 210-211. | | | | | |
| | BQ | Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Decker, Inc., New York, NY, 1992. | | | | | |
| Continued on page 3 | | | | | | | |
| EXAMINER <i>R Gutierrez</i> | | | | | | DATE CONSIDERED <i>11/4/94</i> | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | | | | |

| | | | |
|---|---|---|--|
| FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office | | ATTORNEY DOCKET NO. <i>4012-113 9233.8DV3</i> | SERIAL NO. <i>To be assigned 09/134,809</i> |
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANT Nnochiri N. Ekwuribe | |
| | | FILING DATE <i>Concurrently herewith August 14, 1998</i> | GROUP <i>1646 1651</i> |
| BR | Pardridge, W.M., "CNS Drug Design Based on Principles of Blood-Brain Barrier Transport," J. Neurochem., 1998, 70 (5): pp. 1781-1792. | | |
| BS | Kroll, R.A., et al., "Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means," 1998 Neurosurgery, 42 (5): pp. 1083-1100. | | |
| BT | Pardridge, W.M., "Blood-Brain Barrier Peptide Transport and Peptide Drug Delivery to the Brain," Amer. Chem Soc., 1995, pp: 265-296. | | |
| BU | Banks, W.A., et al., "Passage of Peptides Across the Blood-Brain Barrier: Pathophysiological Perspectives," Life Sciences, 1996, 59 (23), pp: 1923-1943. | | |
| BV | Fix, J.A., "Oral Controlled Release Technology for Peptides: Status and Future Prospects," Pharm. Res., 1996, 13 (12): pp: 1760-1763. | | |
| BW | Terasaki, T., et al., "Oligopeptide Drug Delivery to the Brain," Amer. Chem. Soc. 1995, pp: 297-316. | | |
| BX | Bodor, N., et al., "Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism," Amer. Chem. Soc., 1995, p:317-337. | | |
| BY | Nestor, J., "Improved Duration of Action of Peptide Drugs," Amer. Chem Soc. 1995, pp:449-471. | | |
| BZ | Santiago, N. et al., "Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 116-117. | | |
| CA | Banting, R. G., et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1922, 12: pp. 141-146. | | |
| CB | Brange, J. et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 715-726. | | |
| CC | Nucci, et al., "The Therapeutic Value of Poly(ethylene glycol) - Modified Proteins," Ac. Drug. Del. Rev. 1991, 6: pp. 133-151. | | |
| CD | Brange, J. et al., "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 727-734. | | |
| CE | Robbins, D. C. et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients," Diabetes, 1987, 36: pp. 838-841. | | |
| CF | Maislos, M. et al., "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin," J. Clin. Invest., 1986, 77: pp. 717-723. | | |
| CG | Ratner, R. E. et al., "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: pp. 728-733. | | |
| CH | Oka, K. et al., "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation," Pharm. Res., 1990, 7 (8): pp. 852-855. | | |
| CI | Saffran, M. et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: pp. 1081-1084. | | |
| CJ | Abuchowski, A. and F. F. Davis, "Soluble Polymer-Enzyme Adducts," pp. 368-383, Enzymes as Drugs; J. S. Holcberg, John Wiley, 1981. | | |
| CK | Akiyama, M. et al., "The Synthesis of New Derivatives of 1- β -D-Arabinofuranosylcytosine," Chem. Pharm. Bull., 1978, 26(3): p. 981. | | |
| CL | Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1- β -D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): pp. 1159-1162. | | |
| Continue on Page 4 | | | |
| EXAMINER <i>R. Gutierrez</i> | DATE CONSIDERED <i>11/4/04</i> | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | |

| | | | | |
|---|---|---|--|--|
| FORM PTO-1449 | | US Dept. of Commerce Patent and Trademark Office | ATTORNEY DOCKET NO. <i>4012-113 9233.8DV3</i> | SERIAL NO. <i>To be assigned 09/134,803</i> |
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANT Nnochiri N. Ekwuribe | | |
| | | FILING DATE <i>Concurrently herewith August 14, 1998</i> | GROUP <i>1651 1646-</i> | |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | |
| CM | Baker, D. C. et al., "Prodrugs of 9- β -D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'- (O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): pp. 1218-1221. | | | |
| CN | Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): pp. 6112-6117. | | | |
| CO | Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1- β -D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: pp. 2038-2044. | | | |
| CP | Aoshima, M. et al., " N^1 -Behenoyl-1- β -D-Arabinofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: pp. 2481-2486. | | | |
| CQ | Zalipsky, S. et al., "Attachment of Drugs to Polyethylene Glycols," Eur. Polym. J., 1983, 19(12): pp. 1177-1183. | | | |
| CR | Tsuzuki, N., et al., "Rapid Communication. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug: Antinociceptive Effects of [D-Ala ²] Leu-Enkephalin Derivatives Conjugated with the 1-Adamantane Moiety," Biochemical Pharmacology, 1991, 41 (4): pp. R5-R8. | | | |
| CS | Wagner, J., et al., "Neuropharmacology of Endogenous Opioid Peptides," Psychopharmacology: The Fourth Generation of Progress, 1995, pp. 519-529. | | | |
| CT | Horvat, J., et al., "Synthesis and Biological Activity of [Leu ⁵] Enkephalin Derivatives Containing D-Glucose," J. Peptide Protein Res., 1988, 31, pp. 499-507. | | | |
| CU | Shashoua V.E., et al., " γ -Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ -Aminobutyric Acid," J. Med. Chem., 1984, 27 (5), pp: 660-664. | | | |
| CV | Brewster, M., et al., "Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat," J. Pharm. Studies," 1995, 84 (7), pp: 791-793. | | | |
| CW | Chen, C., et al., "Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN ^{2,5}] Enkephalin in Rats," Pharm. Res. J., 14, pp: 345-350. | | | |
| CX | Bodor, N., et al., "A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism," Science, 1992, 257, pp: 1698-1702. | | | |
| CY | Sim, L., et al., "In vitro Autoradiography of Receptor-Activated G Proteins in Rat Brain by Agonist-stimulated Guanylyl 5'-[γ [³⁵ S]thio]-Triphosphate Binding," Proc. Natl. Acad. Sci., USA, 1995, 92, pp: 7242-7246. | | | |
| CZ | Weber, S.J., et al., "Whole Body and Brain Distribution of [³ H]Cyclic [D-PEN ² , D-PEN ⁵] Enkephalin after Intraperitoneal, Intravenous, Oral and Subcutaneous Administration," J. Pharm. Exper. Ther., 1992, 263 pp: 1308-1316. | | | |
| DA | Alyautdin, R.N., "Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles," Pharm. Res. J., 1997, 14, pp: 325-328. | | | |
| DB | Chiou, G.C.Y., et al., "Systemic Delivery of Enkephalin Peptide through Eyes," Life Sciences, 1988, 43, pp: 509-514. | | | |
| DC | Sakaeda, T., et al., "Conjugation with L-Glutamic Acid for Brain Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1986, 23, pp: 607-608. | | | |
| Continue on Page 5 | | | | |
| EXAMINER <i>R.G. STOMER</i> | DATE CONSIDERED <i>11/14/04</i> | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | |

| | | | |
|---|----|--|--|
| FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office | | ATTORNEY DOCKET NO. <i>#012-113 9233.8D13</i> | SERIAL NO. <i>To be assigned 09/134,803</i> |
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANT Nnochiri N. Ekwuribe | |
| | | FILING DATE <i>Concurrently herewith August 14, 1998</i> | GROUP <i>1646 1651</i> |
| | DD | Chun., W., et al., "Transmucosal Delivery of Methionine Enkephalin. I: Solution Stability and Kinetics of Degradation in Various Rabbit Mucosa Extracts," J. Pharm. Sci., 1993, 82 (4), pp: 373-378. | |
| | DE | Brewster, M.E., et al., "Efficacy of a 3-Substituted Versus 17-Substituted Chemical Delivery System for Estradiol Brain Targeting," J. Pharm. Sci., 1994, pp: A-E. | |
| | DF | Mosnaim, A.D., et al., "Studies of the in Vitro Human Plasma Degradation of Methionine-Enkephalin," Gen. Pharmac., 1988, 19 (5), pp: 729-733. | |
| | DG | Weber, S.J., et al., "Distribution and Analgesia of [³ H]D-PEN ² , D-PEN ⁵] Enkephalin and Two Halogenated Analogs after Intravenous Administration," J. Pharm. Exper. Ther., 1991, 259, pp: 1109-1112. | |
| | DH | Brewster, M.E., et al., "Effect of Molecular Manipulation on the Estrogenic Activity of a Brain-Targeting Estradiol Chemical Delivery System," J. Med. Chem., 1994, 37, pp: 4237-4244 | |
| | DI | Pardridge, W.M., "New Approaches to Drug Delivery Through the Blood-Brain Barrier," Trends in Biotechnology, 1994, pp: 239-245. | |
| | DJ | Shashoua, V.E., et al., "N-Docosahexaenoyl, 3 Hydroxytyramine: A Dopaminergic Compound that Penetrates the Blood-Brain Barrier and Suppresses Appetite," Life Sciences, 58 (16), pp: 1347-1354. | |
| | DK | Gibson, A.M., et al., "Specificity of Action of Human Brain Alanyl Aminopeptidase on Leu-Enkephalin and Dynorphin-Related Peptides," Neuropeptides, 1989, 13, pp: 259-262. | |
| | DL | Prokai-Tatrai, K., et al., "Brain-Targeted Delivery of a Leucine-Enkephalin Analogue by Retrometabolic Design," J. Med. Chem., 1996, 39 (24). | |
| Continue on Page | | | |
| EXAMINER <i>R. G. Tammuz</i> | | DATE CONSIDERED <i>11/4/04</i> | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | |

| | | | | | |
|-----------------------------------|---|----|---|--------------------------|-----------------------|
| Substituted form 1449A/PTO | | | | <i>Complete if Known</i> | |
| | | | | Application Number | To be assigned |
| | | | | Filing Date | Concurrently herewith |
| | | | | First Named Inventor | Ekwuribe |
| | | | | | <i>165</i> |
| | | | | | |
| (use as many sheets as necessary) | | | | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 9233.8DV3 |

| | | | |
|--------------------|---------------|-----------------|---------|
| Examiner Signature | R. G. Johnson | Date Considered | 11/4/04 |
|--------------------|---------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.